Quintrio
Home

PHARMACEUTICAL PREPARATIONS

IDEAYA Biosciences, Inc. Common Stock

IDYA

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Last trade $27.45
Day change -$2.91 (-9.58%)
Day range $26.70 – $31.91
Volume 1,493,267
Market cap $2.94B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.94B
Price / earnings
—
Price / book
2.69×
Price / sales
80.35×
EV / sales
73.2×
EV / EBITDA
-5.81×

Profitability

Earnings per share
-$4.34
Return on assets
-34.54%
Return on equity
-38.46%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.04×
Quick ratio
9.04×
Cash ratio
2.71×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$349.8M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IDYA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$10.24M$8.86M$6.56M$10.88M$207.83M$0$0$7M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$10.24M$8.86M$6.56M$10.88M$207.83M$0$0$7M
Selling, general and administrative$26.3M$22.46M$19.38M$18.85M$16.39M$14.58M$13.5M$10.96M
Research and development$121.58M$108.69M$95.73M$86.6M$82.99M$74.23M$70.89M$140.18M
Total operating expenses$147.87M$131.15M$115.1M$105.45M$99.38M$88.81M$84.39M$151.14M
Operating income-$137.63M-$122.29M-$108.54M-$94.57M$108.45M-$88.81M-$84.39M-$144.14M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$125.75M-$112.45M-$98.54M-$83.27M$119.24M-$77.49M-$72.18M-$130.31M
Income taxes$0$0$0$0$0$0$0$0
Net income-$125.75M-$112.45M-$98.54M-$83.27M$119.24M-$77.49M-$72.18M-$130.31M
Net income attributable to common shareholders-$125.75M-$112.45M-$98.54M-$83.27M$119.24M-$77.49M-$72.18M-$130.31M
EBITDA-$137.02M-$121.6M-$107.86M-$93.85M$109.11M-$88.09M-$83.79M-$143.57M
Basic earnings per share-$1.22-$1.22-$1.11-$0.94$1.35-$0.88-$0.82-$1.49
Diluted earnings per share-$1.22-$1.22-$1.11-$0.95$1.33-$0.88-$0.82-$1.49

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

IDEAYA Biosciences reported a Q3 loss of $1.22 per share, beating the consensus estimate of $1.26 loss by 3.18%. The company posted revenues of $10.24 million, surpassing consensus by 14.69%, though this represents a significant decline from $207.83 million in the year-ago quarter. The stock has underperformed the S&P 500 by 18.7% year-to-date and carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Acadia Pharmaceuticals is expected to report Q3 2026 earnings of $0.21 per share, representing a 19.2% year-over-year decline, despite revenues rising 20.2% to $334.87 million. With a negative Earnings ESP of -0.59% and Zacks Rank #3, the company is not considered a compelling earnings-beat candidate. However, Acadia has beaten consensus EPS estimates in 3 of the last 4 quarters, most recently delivering a +200% surprise.

Zacks Investment Research

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IDEAYA Biosciences is expected to report a quarterly loss of $1.26 per share with revenues of $8.93 million for Q3 2026, representing significant year-over-year declines. However, the company has a positive Earnings ESP of +1.50% combined with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus EPS estimates. The company has only beaten estimates once in the last four quarters.

Benzinga

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

IDEAYA Biosciences announced positive Phase 2/3 trial results for darovasertib combined with crizotinib in treating metastatic uveal melanoma. The combination showed a median progression-free survival of 6.9 months versus 3.1 months for standard therapy, with a 37.1% overall response rate compared to 5.8%. The company plans to submit an FDA New Drug Application in the second half of 2026. IDYA shares surged 26.36% in premarket trading.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.